Stimulation of either cholecystokinin receptor subtype reduces while antagonists potentiate or sensitize a morphine-induced excitatory response

[1]  A. G. Nasello,et al.  Opposite modulation of apomorphine- or amphetamine-induced stereotypy by antagonists of CCK receptors. , 2000, European journal of pharmacology.

[2]  L. Felicio,et al.  Differential Role of Cholecystokinin Receptor Subtypes in Opioid Modulation of Ongoing Maternal Behavior , 1999, Pharmacology Biochemistry and Behavior.

[3]  J. Fujimoto,et al.  Antianalgesic action of dynorphin A mediated by spinal cholecystokinin. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[4]  N. Desousa,et al.  The Expression of Behavioral Sensitization to Amphetamine Role of CCKA Receptors , 1999, Pharmacology Biochemistry and Behavior.

[5]  M. Ohsawa,et al.  Possible involvement of protein kinase C in the attenuation of the morphine-induced Straub tail reaction in diabetic mice. , 1998, European journal of pharmacology.

[6]  K. Shen,et al.  Modulation of opioid analgesia, tolerance and dependence by Gs-coupled, GM1 ganglioside-regulated opioid receptor functions. , 1998, Trends in pharmacological sciences.

[7]  Z. Wiesenfeld‐Hallin,et al.  Differential release of cholecystokinin by morphine in rat spinal cord , 1998, Neuroscience Letters.

[8]  J. Fujimoto,et al.  Pentobarbital antagonism of morphine analgesia mediated by spinal cholecystokinin. , 1998, The Journal of pharmacology and experimental therapeutics.

[9]  M. Hamon,et al.  [Interactions between central opioidergic and cholecystokininergic systems in rats: possible significance for the development of of opioid tolerance]. , 1998, Bulletin de l'Academie nationale de medecine.

[10]  F. Benedetti.  Cholecystokinin Type A and Type B Receptors and Their Modulation of Opioid Analgesia , 1997 .

[11]  C. Stein,et al.  Cholecystokinin inhibits peripheral opioid analgesia in inflamed tissue , 1997, Neuroscience.

[12]  W. Rostène,et al.  Nonpeptide antagonists of neuropeptide receptors: tools for research and therapy. , 1997, Trends in pharmacological sciences.

[13]  A I Basbaum,et al.  Cholecystokinin and enkephalin in brain stem pain modulating circuits , 1997, Neuroreport.

[14]  H. Pettit,et al.  Antagonistic modulation between the delta opioid agonist BW373U86 and the mu opioid agonist fentanyl in mice. , 1997, The Journal of pharmacology and experimental therapeutics.

[15]  Z. Wiesenfeld‐Hallin,et al.  CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level , 1997, Neuropeptides.

[16]  F. Benedetti,et al.  THE NEUROBIOLOGY OF PLACEBO ANALGESIA: FROM ENDOGENOUS OPIOIDS TO CHOLECYSTOKININ , 1997, Progress in Neurobiology.

[17]  A. G. Nasello,et al.  Modulation of apomorphine-induced stereotyped behavior by cholecystokinin , 1997, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[18]  F. Benedetti.  The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia , 1996, Pain.

[19]  R. Bridges,et al.  Investigation into the Role of Cholecystokinin (CCK) in the Induction and Maintenance of Maternal Behavior in Rats , 1995, Hormones and Behavior.

[20]  C. Nath,et al.  Morphine-induced straub tail response: mediated by central mu2-opioid receptor. , 1994, European journal of pharmacology.

[21]  M. Misawa,et al.  Effects of diabetes on the morphine-induced Straub tail reaction in mice , 1994, Neuroscience Letters.

[22]  S. Wank,et al.  Cholecystokinin Receptor Family , 1994 .

[23]  J. Fujimoto,et al.  Inhibiting a spinal dynorphin A component enhances intrathecal morphine antinociception in mice. , 1993, Anesthesia and analgesia.

[24]  A. Riley,et al.  An assessment of the interaction between cholecystokinin and the opiates within a drug discrimination procedure , 1993, Pharmacology Biochemistry and Behavior.

[25]  J. Han,et al.  Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of mu-opioid analgesia by CCKB receptor antagonist L-365,260 in rat spinal cord. , 1993, European journal of pharmacology.

[26]  W. Millington,et al.  Cholecystokinin type A and type B receptor antagonists produce opposing effects on cholecystokinin-stimulated beta-endorphin secretion from the rat pituitary. , 1992, The Journal of pharmacology and experimental therapeutics.

[27]  R. Bridges,et al.  Intracerebroventricular cholecystokinin infusions block beta-endorphin-induced disruption of maternal behavior , 1991, Pharmacology Biochemistry and Behavior.

[28]  J. Crawley.  Cholecystokinin-dopamine intearctions , 1991 .

[29]  T. Hökfelt,et al.  PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[30]  R. J. Crosby,et al.  Central and peripheral vagal transport of cholecystokinin binding sites occurs in afferent fibers , 1990, Brain Research.

[31]  S. Otomo,et al.  Dopamine D2 receptors and spinal cord excitation in mice. , 1990, European journal of pharmacology.

[32]  G. Simonnet,et al.  Differential interactions of cholecystokinin and FLFQPQRF-NH2 with μ and δ opioid antinociception in the rat spinal cord , 1990, Neuropeptides.

[33]  R. Bodnar,et al.  Inhibition of deprivation-induced feeding by naloxone and cholecystokinin in rats: Effects of central alloxan , 1990, Brain Research Bulletin.

[34]  S. Iversen,et al.  The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. , 1990, European journal of pharmacology.

[35]  B. Penke,et al.  Cholecystokinin interferes with the thermoregulatory effect of exogenous and endogenous opioids , 1989, Neuropeptides.

[36]  T. K. Gupta,et al.  A STUDY OF CENTRAL NEUROTRANSMITTER MECHANISMS IN MORPHINE‐INDUCED ‘STRAUB REACTION’ IN MICE: ROLE OF CENTRAL DOPAMINE RECEPTORS , 1988, Clinical and experimental pharmacology & physiology.

[37]  P. Mantegazza,et al.  Dissociation of tolerance and dependence to morphine: a possible role for cholecystokinin , 1987, Brain Research.

[38]  J. Morley,et al.  Opioid modulation of appetite , 1983, Neuroscience & Biobehavioral Reviews.

[39]  J. Crawley,et al.  Rapid development of tolerance to the behavioural actions of cholecystokinin , 1983, Nature.

[40]  L. Watkins,et al.  Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. , 1983, Science.

[41]  S. Itoh,et al.  Caerulein and cholecystokinin suppress β-endorphin-induced analgesia in the rat , 1982 .

[42]  J. Rehfeld,et al.  A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: Evidence from immunohistochemistry combined with retrograde tracing , 1980, Neuroscience.

[43]  G. Zetler.  Antagonism of cholecystokinin-like peptides by opioid peptides, morphine or tetrodotoxin. , 1979, European journal of pharmacology.

[44]  S. Iversen,et al.  The effect of morphine applied locally to mesencephalic dopamine cell bodies on spontaneous motor activity in the rat , 1979, Neuroscience Letters.

[45]  J. Rehfeld,et al.  Immunochemical studies on cholecystokinin. II. Distribution and molecular heterogeneity in the central nervous system and small intestine of man and hog. , 1978, The Journal of biological chemistry.

[46]  F. Wilcoxon,et al.  A simplified method of evaluating dose-effect experiments. , 1948, The Journal of pharmacology and experimental therapeutics.